[177Lu]Lu-rhPSMA-10.1 is under clinical development by Blue Earth Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how [177Lu]Lu-rhPSMA-10.1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lutetium (177Lu) rhPSMA-10.1 is under development for the treatment of metastatic castrate-resistant prostate cancer. The therapeutic candidate comprises prostate-specific membrane antigen ligand labelled with the lutetium-177 (177Lu) radionuclide and is administered through intravenous route in the form of solution.
Blue Earth Therapeutics overview
Blue Earth Therapeutics, a subsidiary of Bracco SpA, is a clinical stage radiopharmaceutical company dedicated to the advancement of targeted radiotherapeutics to treat patients who have prostrate cancer. BET is headquartered in Oxford, Oxfordshire, the UK.
For a complete picture of [177Lu]Lu-rhPSMA-10.1’s drug-specific PTSR and LoA scores, buy the report here.